STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial1 with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Help employers find you! Check out all the jobs and post your resume.
